Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer - a ctDNA Guided Phase II Randomized Approach

NCT04680260 is registered in ClinicalTrials.gov with Karen-Lise Garm Spindler as lead sponsor.

NCT NCT04680260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04680260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer - a ctDNA Guided Phase II Randomized Approach
Lead sponsor
Karen-Lise Garm Spindler
Phase
Phase 2
Overall status
Recruiting
Start date
October 25, 2021
Completion date
March 1, 2030
Enrollment
350 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, metastatic cancer